VONJO Drug Patent Profile

When do Vonjo patents expire, and when can generic versions of Vonjo launch?

Vonjo is a drug marketed by Sobi and is included in one NDA. There are three patents protecting this drug.

This drug has seventy-eight patent family members in twenty-eight countries.

The generic ingredient in VONJO is pacritinib citrate. One supplier is listed for this compound. Additional details are available on the pacritinib citrate profile page.

DrugPatentWatch^® Generic Entry Outlook for Vonjo

Vonjo was eligible for patent challenges on February 28, 2026.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 28, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VONJO

International Patents:	78
US Patents:	3
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for VONJO

VONJO is protected by six US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF ADULTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF) WITH A PLATELET COUNT BELOW 50 X 10^9/L.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sobi	VONJO	pacritinib citrate	CAPSULE;ORAL	208712-001	Feb 28, 2022		RX	Yes	Yes
Sobi	VONJO	pacritinib citrate	CAPSULE;ORAL	208712-001	Feb 28, 2022		RX	Yes	Yes
Sobi	VONJO	pacritinib citrate	CAPSULE;ORAL	208712-001	Feb 28, 2022		RX	Yes	Yes

International Patents for VONJO

When does loss-of-exclusivity occur for VONJO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Croatia

Denmark

European Patent Office

Hong Kong

Israel

Japan

Malaysia

Mexico

New Zealand

Poland

Portugal

Russian Federation

Singapore

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VONJO around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E469158
Australia	2006316071
Australia	2006316072

Investment Scenario and Fundamentals Analysis for VONJO

Last updated: February 20, 2026

What Is VONJO and Its Market Position?

VONJO (tucatinib) is an oral tyrosine kinase inhibitor developed by Seattle Genetics. It targets HER2-positive breast cancer, specifically in patients with metastatic disease. Approved by the FDA in April 2020, VONJO demonstrates efficacy in combination with trastuzumab and capecitabine for treating HER2-positive metastatic breast cancer after at least two prior anti-HER2 based regimens.

It has received supplemental approvals in specific indications, including early-stage HER2-positive breast cancer in combination with trastuzumab and chemotherapy. Given its targeted mechanism, VONJO operates in a high-growth segment of oncology therapeutics.

Market Opportunity and Competitive Landscape

Addressable Market Size

• HER2-positive breast cancer prevalence: Estimated at 15-20% of all breast cancers.
• US estimates: 300,000 new breast cancer diagnoses annually, translating to approximately 45,000–60,000 HER2-positive cases.
• The metastatic subset is roughly 20% of new diagnoses, representing approximately 60,000 new metastatic HER2-positive patients annually in the US.

Market Penetration

• Current treatment options include trastuzumab, pertuzumab, ado-trastuzumab emtansine (Kadcyla), lapatinib, neratinib, and tucatinib in combination regimens.
• VONJO faces competition primarily from other HER2-targeted therapies, including newer ADCs and tyrosine kinase inhibitors.
• Pipeline drugs and biosimilars could influence market share.

Revenue Projections

• Assumptions include steady uptake in eligible patient populations and expanding indications.
• Estimated peak sales by 2027 range between $1.5 billion and $2 billion globally, assuming market acceptance and promotional activities.

Clinical and Regulatory Fundamentals

Efficacy and Safety Profile

• Phase 3 HER2CLIMB trial demonstrated a 46% reduction in progression or death risk versus placebo.
• Median progression-free survival (PFS): 7.8 months vs. 5.4 months.
• Overall survival (OS): 21.9 months vs. 17.4 months.
• Safety profile acceptable, with diarrhea and hepatotoxicity as noted adverse effects.

Regulatory Status

• Approved by FDA under accelerated pathway based on demonstration of clinical benefit.
• Regulatory filings in Europe and Asia are ongoing or submitted.
• Future indications include earlier lines of therapy and combination regimens.

R&D and Commercial Considerations

Patent and Exclusivity

• US patent rights extend to 2036.
• Regulatory exclusivity through 2025–2027, depending on jurisdiction and data exclusivity periods.

Manufacturing and Supply Chain

• Manufactured through Seattle Genetics’ established supply lines, with capacity expansion underway.
• Commercial expansion aimed at global markets, especially Europe, Asia-Pacific.

Cost and Pricing

• List price in the US approximately $14,000 per month.
• Price adjustments expected based on negotiations, insurance reimbursement, and market competition.

Investment Risks and Challenges

• Market competition: Dominance of existing therapies could slow adoption.
• Regulatory hurdles: Future indications require additional clinical data.
• Pricing pressures: Payers scrutinize high-cost oncology drugs.
• Pipeline threats: Emerging therapies targeting HER2, including ADCs and bispecifics, could diminish VONJO’s competitive edge.

Investment Fundamentals Summary

Metric	Data/Estimate
Peak global sales	$1.5–2 billion (2027)
Current annual sales (2022)	~$200 million (estimated)
Market share goal	~25–30% of HER2 metastatic breast cancer segment
Patent expiration	2036
Development phase	Approved, with ongoing expanded indications

Key Takeaways

• VONJO holds a niche in HER2-positive metastatic breast cancer, with growing indications.
• Its clinical efficacy and safety support market penetration, but competition intensifies.
• Regulatory and patent protections provide a pathway to revenue stability through 2036.
• Revenue potential hinges on market acceptance, pricing strategies, and pipeline success.
• Risks include regulatory delays, competitive pressures, and payer restrictions.

FAQs

1. What are the main competitors to VONJO?
Main competitors include other HER2-targeted therapies like trastuzumab emtansine (Kadcyla), tucatinib, and emerging ADCs and TKIs such as margetuximab and neratinib.

2. How does VONJO’s efficacy compare to other HER2 drugs?
VONJO improves PFS and OS in heavily pretreated patients, with a distinct safety profile. It offers a different mechanism suitable for combination use post multiple prior treatments.

3. What are the key regulatory milestones ahead?
Further approvals for earlier lines of therapy and in combination with other drugs are expected, with ongoing trials supporting broader use.

4. How significant are patent protections for future revenue?
Patents extending to 2036 protect exclusivity, delaying generic entry and maintaining pricing power.

5. What potential market challenges could impact revenue?
Price competition, payer reimbursement policies, and a crowded therapeutic landscape could limit sales growth.

---

Sources:

[1] Seattle Genetics. (2022). VONJO (tucatinib) Prescribing Information.
[2] U.S. Food and Drug Administration. (2020). FDA approves tucatinib for HER2-positive metastatic breast cancer.
[3] Global Data. (2022). HER2-positive breast cancer market analysis.
[4] IQVIA. (2022). Oncology drug sales data.
[5] ClinicalTrials.gov. (2023). HER2CLIMB trial details.